ALK+-话题@MedSci

#ALK+#

15篇内容 | 306人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1779683, encodeId=fabe1e796833e, content=<a href='/topic/show?id=f47023119c' target=_blank style='color:#2F92EE;'>#ALK+#</a>, objectTitle=科学管理ALK-TKI不良反应助力ALK+NSCLC长生存, objectType=article, longId=734757, objectId=a1cee34757b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a1cee34757b5, replyNumber=0, likeNumber=50, createdTime=2023-05-25, rootId=0, userName=tcm99hq, userId=74c2229, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a1cee34757b5, moduleTitle=科学管理ALK-TKI不良反应助力ALK+NSCLC长生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a1cee34757b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1779682, encodeId=11ea1e7968250, content=<a href='/topic/show?id=f47023119c' target=_blank style='color:#2F92EE;'>#ALK+#</a>, objectTitle=J Thorac Oncol：Lorlatinib（劳拉替尼）治疗ALK+ NSCLC患者进展后继续使用仍然有效, objectType=article, longId=294238, objectId=ea07294238cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea07294238cf, replyNumber=0, likeNumber=34, createdTime=2022-02-07, rootId=0, userName=tcm99hq, userId=74c2229, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea07294238cf, moduleTitle=J Thorac Oncol：Lorlatinib（劳拉替尼）治疗ALK+ NSCLC患者进展后继续使用仍然有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea07294238cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1779681, encodeId=52dd1e796816b, content=<a href='/topic/show?id=f47023119c' target=_blank style='color:#2F92EE;'>#ALK+#</a>, objectTitle=Blood：Brentuximab vedotin联合化疗治疗ALK+间变性大细胞淋巴瘤, objectType=article, longId=213718, objectId=fd62213e1849, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd62213e1849, replyNumber=0, likeNumber=38, createdTime=2021-11-08, rootId=0, userName=tcm99hq, userId=74c2229, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd62213e1849, moduleTitle=Blood：Brentuximab vedotin联合化疗治疗ALK+间变性大细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd62213e1849)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1779680, encodeId=e94b1e7968063, content=<a href='/topic/show?id=f47023119c' target=_blank style='color:#2F92EE;'>#ALK+#</a>, objectTitle=Lung Cancer：布加替尼（brigatinib）治疗既往治疗过的ALK+转移性非小细胞肺癌患者的疗效：真实世界研究, objectType=article, longId=213524, objectId=54582135246b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54582135246b, replyNumber=0, likeNumber=38, createdTime=2021-10-17, rootId=0, userName=tcm99hq, userId=74c2229, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54582135246b, moduleTitle=Lung Cancer：布加替尼（brigatinib）治疗既往治疗过的ALK+转移性非小细胞肺癌患者的疗效：真实世界研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=54582135246b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1779679, encodeId=9c6c1e79679c7, content=<a href='/topic/show?id=f47023119c' target=_blank style='color:#2F92EE;'>#ALK+#</a>, objectTitle=J Thorac Oncol：布里加替尼治疗晚期ALK+NSCLC患者的初步结果, objectType=article, longId=210605, objectId=efad2106052b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=efad2106052b, replyNumber=0, likeNumber=37, createdTime=2021-08-07, rootId=0, userName=tcm99hq, userId=74c2229, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=efad2106052b, moduleTitle=J Thorac Oncol：布里加替尼治疗晚期ALK+NSCLC患者的初步结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=efad2106052b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1779678, encodeId=63291e79678b5, content=<a href='/topic/show?id=f47023119c' target=_blank style='color:#2F92EE;'>#ALK+#</a>, objectTitle=Blood：IL10RA调控NPM1-ALK+间变性大细胞淋巴瘤对克唑替尼的敏感性, objectType=article, longId=196880, objectId=a6fb196880ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a6fb196880ea, replyNumber=0, likeNumber=41, createdTime=2021-05-14, rootId=0, userName=tcm99hq, userId=74c2229, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a6fb196880ea, moduleTitle=Blood：IL10RA调控NPM1-ALK+间变性大细胞淋巴瘤对克唑替尼的敏感性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a6fb196880ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1779676, encodeId=0e9e1e7967656, content=<a href='/topic/show?id=f47023119c' target=_blank style='color:#2F92EE;'>#ALK+#</a>, objectTitle=WCLC 2019：Alectinib治疗克唑替尼耐药性的ALK+ NSCLC, objectType=article, longId=179242, objectId=f5951e9242cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f5951e9242cd, replyNumber=0, likeNumber=33, createdTime=2020-06-14, rootId=0, userName=tcm99hq, userId=74c2229, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f5951e9242cd, moduleTitle=WCLC 2019：Alectinib治疗克唑替尼耐药性的ALK+ NSCLC, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f5951e9242cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1779677, encodeId=f2651e79677ce, content=<a href='/topic/show?id=f47023119c' target=_blank style='color:#2F92EE;'>#ALK+#</a>, objectTitle=PLos One：阿来替尼与克唑替尼作为ALK+晚期非小细胞肺癌一线治疗的成本-疗效比较, objectType=article, longId=186445, objectId=bda2186445a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bda2186445a1, replyNumber=0, likeNumber=32, createdTime=2020-03-31, rootId=0, userName=tcm99hq, userId=74c2229, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bda2186445a1, moduleTitle=PLos One：阿来替尼与克唑替尼作为ALK+晚期非小细胞肺癌一线治疗的成本-疗效比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bda2186445a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1779675, encodeId=b1931e79675de, content=<a href='/topic/show?id=f47023119c' target=_blank style='color:#2F92EE;'>#ALK+#</a>, objectTitle=Blood：PD-L1在ALK+间变性大细胞淋巴瘤中表达上调的分子机制, objectType=article, longId=167595, objectId=5ad816e5956b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ad816e5956b, replyNumber=0, likeNumber=38, createdTime=2019-08-13, rootId=0, userName=tcm99hq, userId=74c2229, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ad816e5956b, moduleTitle=Blood：PD-L1在ALK+间变性大细胞淋巴瘤中表达上调的分子机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ad816e5956b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1779672, encodeId=6f331e79672ca, content=<a href='/topic/show?id=f47023119c' target=_blank style='color:#2F92EE;'>#ALK+#</a>, objectTitle=青年群体的智慧，探索ALK+一线34.8个月PFS耐药后的治疗, objectType=article, longId=150114, objectId=da111501140c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=da111501140c, replyNumber=0, likeNumber=21, createdTime=2019-06-19, rootId=0, userName=tcm99hq, userId=74c2229, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=da111501140c, moduleTitle=青年群体的智慧，探索ALK+一线34.8个月PFS耐药后的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=da111501140c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1779674, encodeId=b8a11e79674cf, content=<a href='/topic/show?id=f47023119c' target=_blank style='color:#2F92EE;'>#ALK+#</a>, objectTitle=ALK+脑膜转移晚期肺腺癌患者诊疗带来的总结与思考, objectType=article, longId=157052, objectId=6ee215e0529f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ee215e0529f, replyNumber=0, likeNumber=46, createdTime=2019-04-27, rootId=0, userName=tcm99hq, userId=74c2229, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ee215e0529f, moduleTitle=ALK+脑膜转移晚期肺腺癌患者诊疗带来的总结与思考, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ee215e0529f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1779673, encodeId=41d71e796730f, content=<a href='/topic/show?id=f47023119c' target=_blank style='color:#2F92EE;'>#ALK+#</a>, objectTitle=欧盟委员会批准ALUNBRIG（brigatinib）治疗ALK+非小细胞肺癌, objectType=article, longId=154589, objectId=7779154589ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7779154589ed, replyNumber=0, likeNumber=28, createdTime=2019-07-27, rootId=0, userName=tcm99hq, userId=74c2229, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7779154589ed, moduleTitle=欧盟委员会批准ALUNBRIG（brigatinib）治疗ALK+非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7779154589ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1779670, encodeId=1d8a1e796702e, content=<a href='/topic/show?id=f47023119c' target=_blank style='color:#2F92EE;'>#ALK+#</a>, objectTitle=重磅！FDA授予罗氏抗癌药Alecensa第2个突破性药物资格，一线治疗ALK+NSCLC领域即将上演巅峰对决, objectType=article, longId=79383, objectId=2781e9383a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2781e9383a5, replyNumber=0, likeNumber=31, createdTime=2017-02-07, rootId=0, userName=tcm99hq, userId=74c2229, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2781e9383a5, moduleTitle=重磅！FDA授予罗氏抗癌药Alecensa第2个突破性药物资格，一线治疗ALK+NSCLC领域即将上演巅峰对决, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2781e9383a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1779671, encodeId=985e1e7967114, content=<a href='/topic/show?id=f47023119c' target=_blank style='color:#2F92EE;'>#ALK+#</a>, objectTitle=ALK+非小细胞肺癌：罗氏在肿瘤领域的又一封王之地, objectType=article, longId=92823, objectId=faeb92823d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=faeb92823d0, replyNumber=0, likeNumber=39, createdTime=2018-02-15, rootId=0, userName=tcm99hq, userId=74c2229, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=faeb92823d0, moduleTitle=ALK+非小细胞肺癌：罗氏在肿瘤领域的又一封王之地, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=faeb92823d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1779669, encodeId=5d1e1e796692f, content=<a href='/topic/show?id=f47023119c' target=_blank style='color:#2F92EE;'>#ALK+#</a>, objectTitle=重磅！诺华新型靶向抗癌药Zykadia一线治疗晚期ALK+肺癌III期临床获得成功，辉瑞霸主地位将不保, objectType=article, longId=78707, objectId=88a4e870731, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=88a4e870731, replyNumber=0, likeNumber=36, createdTime=2017-06-19, rootId=0, userName=tcm99hq, userId=74c2229, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=88a4e870731, moduleTitle=重磅！诺华新型靶向抗癌药Zykadia一线治疗晚期ALK+肺癌III期临床获得成功，辉瑞霸主地位将不保, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=88a4e870731)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

ALK+

2020-05-29

tcm99hq (审核中...)

前往app查看评论内容

#ALK+#

科学管理ALK-TKI不良反应助力ALK+NSCLC长生存

2023-05-25

tcm99hq (审核中...)

前往app查看评论内容

#ALK+#

J Thorac Oncol：Lorlatinib（劳拉替尼）治疗ALK+ NSCLC患者进展后继续使用仍然有效

2022-02-07

tcm99hq (审核中...)

前往app查看评论内容

#ALK+#

Blood：Brentuximab vedotin联合化疗治疗ALK+间变性大细胞淋巴瘤

2021-11-08

tcm99hq (审核中...)

前往app查看评论内容

#ALK+#

Lung Cancer：布加替尼（brigatinib）治疗既往治疗过的ALK+转移性非小细胞肺癌患者的疗效：真实世界研究

2021-10-17

tcm99hq (审核中...)

前往app查看评论内容

#ALK+#

J Thorac Oncol：布里加替尼治疗晚期ALK+NSCLC患者的初步结果

2021-08-07

tcm99hq (审核中...)

前往app查看评论内容

#ALK+#

Blood：IL10RA调控NPM1-ALK+间变性大细胞淋巴瘤对克唑替尼的敏感性

2021-05-14

tcm99hq (审核中...)

前往app查看评论内容

#ALK+#

WCLC 2019：Alectinib治疗克唑替尼耐药性的ALK+ NSCLC

2020-06-14

tcm99hq (审核中...)

前往app查看评论内容

#ALK+#

PLos One：阿来替尼与克唑替尼作为ALK+晚期非小细胞肺癌一线治疗的成本-疗效比较

2020-03-31

tcm99hq (审核中...)

前往app查看评论内容

#ALK+#

Blood：PD-L1在ALK+间变性大细胞淋巴瘤中表达上调的分子机制

2019-08-13

tcm99hq (审核中...)

前往app查看评论内容

#ALK+#

青年群体的智慧，探索ALK+一线34.8个月PFS耐药后的治疗

2019-06-19

tcm99hq (审核中...)

前往app查看评论内容

#ALK+#

ALK+脑膜转移晚期肺腺癌患者诊疗带来的总结与思考

2019-04-27

tcm99hq (审核中...)

前往app查看评论内容

#ALK+#

欧盟委员会批准ALUNBRIG（brigatinib）治疗ALK+非小细胞肺癌

2019-07-27

tcm99hq (审核中...)

前往app查看评论内容

#ALK+#

重磅！FDA授予罗氏抗癌药Alecensa第2个突破性药物资格，一线治疗ALK+NSCLC领域即将上演巅峰对决

2017-02-07

tcm99hq (审核中...)

前往app查看评论内容

#ALK+#

ALK+非小细胞肺癌：罗氏在肿瘤领域的又一封王之地

2018-02-15

tcm99hq (审核中...)

前往app查看评论内容

#ALK+#

重磅！诺华新型靶向抗癌药Zykadia一线治疗晚期ALK+肺癌III期临床获得成功，辉瑞霸主地位将不保

2017-06-19

科室
- - 订阅+
  - 更多科室
工具
服务